In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biosensors International Group Ltd.

www.biosensors.com

Latest From Biosensors International Group Ltd.

Boston Scientific’s Synergy Stent Narrowly Outperforms Biosensors’ Biomatrix NeoFlex In Danish Study

Data from the 2,770-patient randomized SORT OUT VIII trial showed Boston Scientific’s Synergy everolimus-eluting stent is noninferior to Biosensor’s Biomatrix NeoFlex Biolimus-eluting stent for the endpoint of target lesion failure, but the procedure failure-rate was lower in the Synergy patients, which may have led to lower overall rates of myocardial infarction.

Clinical Trials Commercial

Market Intel: The Changing Dynamics Of Newer-Generation Drug-Eluting Stents

The global vascular stents market is expected to reach $8.8bn by 2021, driven primarily by the growing prevalence of cardiovascular disease, the leading cause of death worldwide. Limitations of current stent products are fueling innovations by the three big heart players - Abbott, Boston Scientific and Medtronic - as well as startups to develop next-generation drug-eluting and bioresorbable stents that can reduce the risk of adverse event. This feature looks more closely at the competitive landscape of the overall vascular stent market focusing in particular on the changing dynamics of drug-eluting stents, which is the largest and second-fastest segment in this overall market, including its use for treating peripheral artery disease, along with physician surveys and perspectives.

Cardiovascular Market Intelligence

TCT 2016: EXCEL And NOBLE Give Different Answers On Stenting Vs. Surgery For Left-Main Disease

NOBLE found that the five-year risk of major adverse events was higher after stenting compared to coronary bypass surgery to treat unprotected left-main coronary artery disease, while EXCEL found that stenting is safer than surgery in patients with this condition and low anatomic complexity.

Research & Development Clinical Trials

TCT 2016: Three-Year ABSORB II Data Fail To Show The Hoped-For Long-Term Benefit Of Bioresorbable Stent

The data, presented Oct. 30 at the TCT Conference in Washington, DC, also showed higher rates of device-related adverse events including myocardial infarction with Abbott’s Absorb bioresorbable stent than a metallic drug-eluting stent, but the study was not powered to show differences in clinical endpoints, so this adverse safety signal must be evaluated in future clinical trials.

Cardiovascular Clinical Trials
See All

Company Information

  • Industry
  • Medical Devices
    • Diagnostic Imaging Equipment & Supplies
    • Implantable Devices
    • Surgical Equipment & Devices
  • Pharmaceuticals
    • Drug Delivery
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Singapore
  • Parent & Subsidiaries
  • Biosensors International Group Ltd.
  • Senior Management
  • Jose Calle Gordo, PhD, CEO
    Ronald H Ede, CFO
  • Contact Info
  • Biosensors International Group Ltd.
    Phone: (65) 6213 5777
    36 Jalan Tukang
    Singapore , 619266
    Singapore
Advertisement
Advertisement
UsernamePublicRestriction

Register